In Brief: Amersham Pharmacia Biotech
This article was originally published in The Gray Sheet
Executive Summary
Amersham Pharmacia Biotech: Aims to expand its gene mutation analysis business via acquisition of an exclusive worldwide license from Avitech Diagnostics enabling commercialization of products based on Avitech's EMD proprietary gene mutation scanning technology for research and diagnostic use. Under the terms of the deal, Amersham Pharmacia Biotech "will establish partnership programs with diagnostic product companies, based on EMD and other proprietary technologies," the firm states. Avitech retains rights to provide genome research, pharmacogenomic and diagnostic services based on the EMD technology...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.